3 Antibiotic Ingredient, Oral Rehydration and Edible Oil Stocks With a Strong Future Roadmap: Concord Biotech, FDC and AWL Agri Business
- October 19, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Concord Biotech Rs 1,339.00, P/E 51.00. FDC Rs 356.25, P/E 18.05. AWL Agri Rs 187.30, P/E 20.49. Closing prices of 14 Oct 2026.
Quick Answer
Antibiotic ingredient, oral rehydration and edible oil stocks with the clearest long-term roadmaps today include Concord Biotech in fermentation-based active ingredients, including immunosuppressants and anti-infectives, FDC in oral rehydration products such as Electral along with eye, ear and anti-infective formulations and AWL Agri in edible oils, packaged foods and staples sold under the Fortune brand. P/E stands at 51.00 for Concord Biotech (industry 37.59), 18.05 for FDC (industry 37.59) and 20.49 for AWL Agri (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Antibiotic ingredient, oral rehydration and edible oil stocks give investors exposure to drug ingredients, everyday health products and kitchen staples. Volumes, pricing and margins decide how much of that demand turns into profit.
This list covers three antibiotic ingredient, oral rehydration and edible oil stocks: Concord Biotech for fermentation-based active ingredients, including immunosuppressants and anti-infectives, FDC for oral rehydration products such as Electral along with eye, ear and anti-infective formulations and AWL Agri Business for edible oils, packaged foods and staples sold under the Fortune brand. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Antibiotic Ingredient, Oral Rehydration and Edible Oil Stocks?
Antibiotic ingredient, oral rehydration and edible oil stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Antibiotic Ingredient, Oral Rehydration and Edible Oil Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three antibiotic ingredient, oral rehydration and edible oil stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Concord Biotech | 1,339.00 | 13,913 | 51.00 | 37.59 | 12.94% | 0.00 |
| FDC | 356.25 | 5,281 | 18.05 | 37.59 | 11.32% | 0.01 |
| AWL Agri Business | 187.30 | 23,732 | 20.49 | 34.85 | 9.98% | 0.11 |
Among healthcare and consumer stocks, Concord Biotech trades at a premium to the industry P/E, while FDC and AWL Agri trade at a discount.
Why Do Antibiotic Ingredient, Oral Rehydration and Edible Oil Stocks Have a Strong Roadmap in India?
Antibiotic ingredient, oral rehydration and edible oil stocks have a strong roadmap in India because drug ingredient demand, everyday health products and household food spending keep adding volumes for these firms. Three drivers stand out.
- Ingredient demand: Drug makers buy fermentation-based ingredients.
- Everyday health: Families buy rehydration and eye and ear care products.
- Kitchen staples: Families buy edible oils and packaged foods.
Concord Biotech: Fermentation Ingredients Drive the Pipeline
Concord Biotech’s roadmap rests on fermentation-based active ingredients, including immunosuppressants and anti-infectives, with regulated market exports supporting revenue.
Revenue grew from Rs 736.35 crore in FY22 to Rs 1,107.25 crore in FY26, a 50.4% rise. FY26 net profit was Rs 259.23 crore. In Q1 FY27, revenue grew 24.2% to Rs 270.32 crore, and net profit rose 31.0% to Rs 57.70 crore. Operating margin was 39.81% in FY26.
Debt to equity is 0.00 and return on equity is 12.94%. FY26 operating cash flow was Rs 266.88 crore against capital expenditure of Rs 95.15 crore. Concord Biotech paid a dividend of Rs 7.55 per share for FY26, a yield of 0.57%. At a P/E of 51.00 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 51.00 sits above the industry P/E of 37.59, so earnings delivery matters for the valuation.
FDC: Established Brands Drive the Pipeline
FDC’s roadmap rests on oral rehydration products such as Electral along with eye, ear and anti-infective formulations, with established brands supporting steady sales.
Revenue grew from Rs 1,604.01 crore in FY22 to Rs 2,284.45 crore in FY26, a 42.4% rise, and FY26 revenue was 3.9% higher than FY25. FY26 net profit rose 5.5% to Rs 281.42 crore. Over four years, net profit rose from Rs 216.16 crore in FY22 to Rs 281.42 crore. In Q1 FY27, revenue grew 4.6% to Rs 715.35 crore, and net profit rose 9.2% to Rs 132.49 crore. Operating margin was 20.21% in FY26 and 28.56% in Q1 FY27 against 27.12% a year earlier.
Debt to equity is 0.01 and return on equity is 11.32%. FY26 operating cash flow was Rs 200.45 crore against capital expenditure of Rs 186.56 crore. FDC paid a dividend of Rs 5 per share for FY26, a yield of 1.54%. At a P/E of 18.05 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 28.56% against 20.21% for FY26, so margin stability is the figure to follow as volumes grow.
AWL Agri Business: Edible Oils and Staples Build the Next Leg
AWL Agri’s roadmap rests on edible oils, packaged foods and staples sold under the Fortune brand, with a wide distribution network supporting volumes.
Revenue grew from Rs 54,327.16 crore in FY22 to Rs 75,148.47 crore in FY26, a 38.3% rise, and FY26 revenue was 17.6% higher than FY25. FY26 net profit was Rs 990.44 crore. In Q1 FY27, revenue grew 16.5% to Rs 20,116.91 crore, and net profit rose 47.7% to Rs 351.39 crore. Operating margin was 3.38% in FY26 and 3.90% in Q1 FY27 against 3.39% a year earlier.
Debt to equity is 0.11 and return on equity is 9.98%. FY26 operating cash flow was Rs 3,928.34 crore against capital expenditure of Rs 833.37 crore. AWL Agri paid a dividend of Rs 1 per share for FY26, a yield of 0.55%. At a P/E of 20.49 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: Net profit margin is only 1.3%, so small cost changes move earnings.
Best Antibiotic Ingredient, Oral Rehydration and Edible Oil Stocks in India: Concord Biotech vs FDC vs AWL Agri on Key Financials
Among the best antibiotic ingredient, oral rehydration and edible oil stocks in India, Concord Biotech leads on FY26 operating margin and Q1 FY27 revenue growth; FDC leads on the lowest P/E and dividend yield; AWL Agri leads on Q1 FY27 net profit growth. The table puts the numbers side by side.
| Metric | Concord Biotech | FDC | AWL Agri |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 1,107.25 | 2,284.45 | 75,148.47 |
| FY26 net profit (Rs Cr) | 259.23 | 281.42 | 990.44 |
| FY26 operating profit margin | 39.81% | 20.21% | 3.38% |
| Q1 FY27 revenue growth (YoY) | 24.2% | 4.6% | 16.5% |
| Q1 FY27 net profit growth (YoY) | 31.0% | 9.2% | 47.7% |
| Return on equity | 12.94% | 11.32% | 9.98% |
| P/E ratio | 51.00 | 18.05 | 20.49 |
| Debt to equity | 0.00 | 0.01 | 0.11 |
| Dividend yield | 0.57% | 1.54% | 0.55% |
| FY26 operating cash flow (Rs Cr) | 266.88 | 200.45 | 3,928.34 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Antibiotic Ingredient, Oral Rehydration and Edible Oil Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen antibiotic ingredient, oral rehydration and edible oil stocks and shortlist antibiotic ingredient, oral rehydration and edible oil stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Antibiotic Ingredient, Oral Rehydration and Edible Oil Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Concord Biotech, FDC and AWL Agri live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare and consumer stocks cover drug ingredients, rehydration products and kitchen staples. Concord Biotech leads on FY26 operating margin and Q1 FY27 revenue growth; FDC leads on the lowest P/E and dividend yield; AWL Agri leads on Q1 FY27 net profit growth.
Across antibiotic ingredient, oral rehydration and edible oil stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the antibiotic ingredient, oral rehydration and edible oil stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Antibiotic Ingredient, Oral Rehydration and Edible Oil Stocks
Which are the best antibiotic ingredient, oral rehydration and edible oil stocks in India with a strong roadmap?
Ans. Concord Biotech, FDC and AWL Agri Business stand out for their roadmaps in drug ingredients, rehydration products and kitchen staples. Return on equity ranges from 9.98% to 12.94%.
Is Concord Biotech a good stock to buy now?
Ans. Concord Biotech has a debt to equity ratio of 0.00, a return on equity of 12.94% and a P/E of 51.00 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Concord Biotech, FDC and AWL Agri?
Ans. The P/E ratio is 51.00 for Concord Biotech (industry 37.59), 18.05 for FDC (industry 37.59) and 20.49 for AWL Agri (industry 34.85). Only Concord Biotech trades at or above the industry multiple.
Which of these antibiotic ingredient, oral rehydration and edible oil stocks has the highest return on equity?
Ans. Concord Biotech has the highest return on equity at 12.94%, followed by FDC at 11.32% and AWL Agri Business at 9.98%.
What are the risks of investing in antibiotic ingredient, oral rehydration and edible oil stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Concord Biotech, FDC and AWL Agri perform in Q1 FY27?
Ans. Concord Biotech reported revenue of Rs 270.32 crore, up 24.2% year on year, and net profit rose 31.0% to Rs 57.70 crore. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore. AWL Agri Business reported revenue of Rs 20,116.91 crore, up 16.5% year on year, and net profit rose 47.7% to Rs 351.39 crore.
Do antibiotic ingredient, oral rehydration and edible oil stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.57% for Concord Biotech, 1.54% for FDC and 0.55% for AWL Agri, based on dividends declared for FY26.
How can I invest in antibiotic ingredient, oral rehydration and edible oil stocks in India?
Ans. You can buy antibiotic ingredient, oral rehydration and edible oil stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
